Methods Of Predicting Response To JNK Inhibitor Therapy

Abstract

This present invention provides methods of treating of accessing/monitoring the responsiveness of a cancer cell to JNK inhibitor therapy.

What is claimed is: 
     
         1 . A method of accessing the effectiveness of a JNK inhibitor treatment regimen of a subject having cancer comprising, obtaining a sample from the subject and detecting:
 a) c-JUN expression, wherein the expression of C-JUN indicates the subject is responsive to a JNK inhibitor treatment;   b) the presence or absence of a mutation in the KRAS polypeptide, wherein the presence of the mutation indicates the subject is responsive to a JNK inhibitor treatment; or   c) the presence or absence of a mutation in the EGFR polypeptide, wherein the presence of the mutation indicates the subject is non-responsive to a JNK inhibitor treatment.   
     
     
         2 . The method of  claim 1 , wherein the JNK inhibitor is JIP-1, CC-410, 1,9-pyrazoloanthrone, 2-benzothiazoleacetonitrile, XG-102, BI78D3 or BI87G9. 
     
     
         3 . The method of  claim 1 , wherein the cancer is melanoma, non-small cell lung cancer or colorectal cancer. 
     
     
         4 . The method of  claim 1 , wherein said subject has not received treatment for the cancer. 
     
     
         5 . The method of  claim 1 , wherein said subject has received treatment for the cancer. 
     
     
         6 . The method of  claim 1 , wherein the method is implemented in a flow-cytometry (FC), immuno-histochemistry (IHC), or immuno-fluorescence (IF) assay format. 
     
     
         7 . The method of  claim 1 , wherein the method is implemented in a polymerase chain reaction (PCR) sequencing assay format. 
     
     
         8 . A method of treating a subject having melanoma comprising identifying a subject having a melanoma expressing c-JUN and administering to the subject a JNK inhibitor. 
     
     
         9 . A method treating a subject having non-small cell lung cancer or colon cancer comprising identifying a subject having a KRAS mutation and administering to the subject a JNK inhibitor. 
     
     
         10 . A method of treating a subject having non-small cell lung cancer comprising identifying a subject not having an EGFR mutation and administering to the subject a JNK inhibitor.